Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results.Paolo A. Ascierto, Vanna Chiarion‐Sileni, Francesco Spagnolo et al.|Journal of Clinical Oncology|2024Cited by 2